Comparing the effects of endogenous and synthetic cannabinoid receptor agonists on survival of gastric cancer cells

详细信息    查看全文

• 作者：A. Ortega^a ; V.M. Garcí ; a-Herná ; ndez^a ; E. Ruiz-Garcí ; a^a ; A. Meneses-Garcí ; a^a ; A. Herrera-Gó ; mez^a ; J.L. Aguilar-Ponce^a ; E. Montes-Serví ; n^b ; O. Prospero-Garcí ; a^c ; S.A. Del Angel^d ; ^{absada@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Gastric cancer cells ; Cannabinoid receptor agonists ; Apoptosis ; Anti-proliferative activity ; Anti-tumor therapy
• 刊名：Life Sciences
• 出版年：2016
• 出版时间：15 November 2016
• 年：2016
• 卷：165
• 期：Complete
• 页码：56-62
• 全文大小：1801 K

文摘

Anti-neoplastic activity induced by cannabinoids has been extensively documented for a number of cancer cell types; however, this topic has been explored in gastric cancer cells only in a limited number of approaches. Thus, the need of integrative and comparative studies still persists.

Materials and methods

In this study we tested and compared the effects of three different cannabinoid receptor agonists-anandamide (AEA), (R)-(+)-methanandamide (Meth-AEA) and CP 55,940 (CP)- on gastric cancer cell morphology, viability and death events in order to provide new insights to the use of these agents for therapeutic purposes.

Key findings

The three agents tested exhibited similar concentration-dependent effects in the induction of changes in cell morphology and cell loss, as well as in the decrease of cell viability and DNA laddering in the human gastric adenocarcinoma cell line (AGS). Differences among the cannabinoids tested were mostly observed in the density of cells found in early and late apoptosis and necrosis, favoring AEA and CP as the more effective inducers of apoptotic mechanisms, and Meth-AEA as a more effective inducer of necrosis through transient and rapid apoptosis.

Significance

Through a comparative approach, our results support and confirm the therapeutic potential that cannabinoid receptor agonists exert in gastric cancer cells and open possibilities to use cannabinoids as part of a new gastric cancer therapy.